Allison E Girasole, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Levodopa | 3 | 2022 | 219 | 1.150 |
Why?
|
| Dyskinesia, Drug-Induced | 2 | 2018 | 163 | 1.110 |
Why?
|
| Neostriatum | 2 | 2015 | 250 | 0.960 |
Why?
|
| Antiparkinson Agents | 1 | 2018 | 184 | 0.580 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2015 | 12 | 0.550 |
Why?
|
| Corpus Striatum | 3 | 2022 | 1221 | 0.550 |
Why?
|
| RGS Proteins | 1 | 2015 | 77 | 0.530 |
Why?
|
| Neuronal Plasticity | 3 | 2022 | 1422 | 0.520 |
Why?
|
| Dopamine Agents | 1 | 2015 | 189 | 0.500 |
Why?
|
| Parkinsonian Disorders | 1 | 2015 | 275 | 0.430 |
Why?
|
| Adrenergic Agonists | 2 | 2012 | 58 | 0.430 |
Why?
|
| Receptors, Adrenergic | 1 | 2011 | 155 | 0.400 |
Why?
|
| Muscarinic Agonists | 1 | 2011 | 87 | 0.390 |
Why?
|
| Receptors, Muscarinic | 1 | 2011 | 156 | 0.390 |
Why?
|
| Interneurons | 1 | 2015 | 577 | 0.370 |
Why?
|
| Neurons | 5 | 2022 | 9338 | 0.320 |
Why?
|
| Parkinson Disease | 1 | 2018 | 2775 | 0.230 |
Why?
|
| Purkinje Cells | 2 | 2022 | 224 | 0.230 |
Why?
|
| Chorea | 1 | 2022 | 74 | 0.200 |
Why?
|
| Dyskinesias | 1 | 2022 | 78 | 0.200 |
Why?
|
| Heart | 2 | 2012 | 4467 | 0.200 |
Why?
|
| Motor Cortex | 2 | 2019 | 986 | 0.190 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 895 | 0.170 |
Why?
|
| Neural Pathways | 2 | 2019 | 2972 | 0.150 |
Why?
|
| Guinea Pigs | 2 | 2012 | 1386 | 0.110 |
Why?
|
| Neurogenesis | 1 | 2019 | 838 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2015 | 23403 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 9734 | 0.100 |
Why?
|
| Learning | 1 | 2021 | 1713 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2012 | 246 | 0.100 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2011 | 67 | 0.100 |
Why?
|
| Angiotensin II | 2 | 2012 | 881 | 0.100 |
Why?
|
| Potassium Channel Blockers | 1 | 2011 | 171 | 0.100 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 152 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 2147 | 0.080 |
Why?
|
| Membrane Potentials | 1 | 2011 | 1137 | 0.080 |
Why?
|
| Animals | 8 | 2022 | 168757 | 0.070 |
Why?
|
| Potassium | 1 | 2011 | 1336 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 1240 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2011 | 1767 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 924 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 18029 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 21827 | 0.060 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2021 | 59 | 0.050 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2021 | 377 | 0.040 |
Why?
|
| Long-Term Potentiation | 1 | 2021 | 293 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2012 | 2788 | 0.040 |
Why?
|
| Presynaptic Terminals | 1 | 2021 | 302 | 0.040 |
Why?
|
| Calcium | 1 | 2011 | 5756 | 0.040 |
Why?
|
| Substantia Nigra | 1 | 2019 | 353 | 0.040 |
Why?
|
| Cerebellum | 1 | 2021 | 1488 | 0.030 |
Why?
|
| Male | 5 | 2022 | 350118 | 0.030 |
Why?
|
| Timolol | 1 | 2012 | 52 | 0.030 |
Why?
|
| Cholinergic Agents | 1 | 2012 | 93 | 0.030 |
Why?
|
| Synapses | 1 | 2021 | 1728 | 0.030 |
Why?
|
| Motor Activity | 1 | 2021 | 2714 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 81183 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 40075 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Female | 3 | 2022 | 380194 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 9146 | 0.010 |
Why?
|
| Humans | 2 | 2021 | 744343 | 0.010 |
Why?
|
| Brain | 1 | 2021 | 26385 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 11727 | 0.010 |
Why?
|